VTE as a Quality Indicator

Author： Goldsmith Myron   Whitelaw George   Cannaday Denise A.  

Publisher： Cambridge Scholars Publishing in association with GSE Research

ISSN： 1540-1405

Source： Journal of the National Comprehensive Cancer Network (JNCCN), Vol.6, Iss.8, 2008-09, pp. : 754-759

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Risk of VTE with Ortho Evra?

By  

Reactions Weekly, Vol. 1, Iss. 1092, 2006-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Ximelagatran reduces risk of VTE

By  

Inpharma, Vol. 1, Iss. 1375, 2003-01 ,pp. : 9-10

Adis International

Access to resources Recommend Favorite

NICE releases guidance on VTE . . .

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 657, 2012-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Quality Indicators for In-Hospital Pharmaceutical Care of Dutch Elderly Patients: Development and Validation of an ACOVE-Based Quality Indicator Set

By Wierenga Peter C.  

Drugs & Aging, Vol. 28, Iss. 4, 2011-04 ,pp. : 295-304

Adis International

Access to resources Recommend Favorite

High VTE rates with thalidomide, lenalidomide

By  

Reactions Weekly, Vol. 1, Iss. 1133, 2007-01 ,pp. : 1-1

Adis International

Access to resources Recommend Favorite